Federica R. Cavallo - Publications

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.

Journal: Pharmaceutics

Published: June 04, 2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances

Published: April 16, 2026

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Journal: HemaSphere

Published: April 02, 2026

A novel approach to characterize the energy cost of human cool-seeking behavior and its individual variability during heat stress.

Journal: American journal of physiology. Regulatory, integrative and comparative physiology

Published: January 14, 2026

WEARnCARE, a decision support system to enhance monitoring of motor performance in Parkinson's disease patient's journey.

Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

Published: December 03, 2025

"Summertime sadness": Striatal dopamine binding decreases during warmer seasons in patients with severe depression.

Journal: Psychiatry research. Neuroimaging

Published: November 29, 2025

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13 TeV.

Journal: Physical review letters

Published: November 24, 2025

Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 11, 2025

Exploring Emerging Therapeutic Targets in Osteosarcoma by Revisiting the Immune and Cancer-Intrinsic Hallmarks of Cancer.

Journal: Cancers

Published: November 07, 2025

Observation of tWZ Production at the CMS Experiment.

Journal: Physical review letters

Published: October 21, 2025

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Journal: Blood advances

Published: October 14, 2025

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Journal: Annals of hematology

Published: October 13, 2025